Table II.
Risk of mammary tumor development in Prevention Study 2
| Treatment comparison | No. of tumors/glands treated | Hazard ratio | 95% Confidence interval | P value |
|---|---|---|---|---|
| i.duc void polymer versus oral free curcumin | 23/60 versus 5/36 | 3.95 | 1.47–10.6 | 0.007 |
| i.duc void polymer versus i.duc free curcumin | 23/60 versus 12/72 | 2.85 | 1.18–6.92 | 0.020 |
| i.duc void polymer versus i.duc NanoCurc | 23/60 versus 13/72 | 2.73 | 1.56–4.78 | < 0.0001 |
| i.duc free curcumin versus oral free curcumin | 12/72 versus 5/36 | 1.38 | 0.46–4.19 | 0.565 |
| i.duc NanoCurc versus oral free curcumin | 13/72 versus 5/36 | 1.45 | 0.62–3.37 | 0.394 |
| i.duc NanoCurc versus i.duc free curcumin | 13/72 versus 12/72 | 1.04 | 0.42–2.59 | 0.925 |